ARC-009

ARC-009 is an antibody-radioisotope conjugate (ARC) currently in the discovery stage for the treatment of oncology indications. Developed by iProgen Biotech, the candidate leverages the company's proprietary site-specific conjugation platform, which utilizes the 'i-Linker' technology to attach therapeutic radioisotopes to monoclonal antibodies. This approach aims to enhance the therapeutic index of radiopharmaceuticals by ensuring stable delivery to the tumor site while minimizing systemic exposure and off-target effects. ARC-009 is being developed as part of an industry partnership, though the specific molecular target and the nature of the radioactive payload have not been publicly disclosed.